Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Healthtrust
Moodys
UBS
Mallinckrodt
Cerilliant
Citi
Farmers Insurance
Express Scripts

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,067,431

« Back to Dashboard

Summary for Patent: 8,067,431
Title:Chemically modified small molecules
Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
Inventor(s): Fishburn; C. Simone (Redwood City, CA), Lechuga-Ballesteros; David (San Jose, CA), Viegas; Tacey (Madison, AL), Kuo; Mei-Chang (Palo Alto, CA), Song; Yuan (Belmont, CA), Gursahani; Hema (Foster City, CA), Leach; Chester (Tijeras, NM)
Assignee: Nektar Therapeutics (San Francisco, CA)
Application Number:12/710,167
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,067,431

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Try a Free Trial
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,067,431

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,034,825 Chemically modified small molecules ➤ Try a Free Trial
9,388,104 Chemically modified small molecules ➤ Try a Free Trial
2,015,197,470 ➤ Try a Free Trial
7,786,133 Chemically modified small molecules ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,067,431

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2758460 ➤ Try a Free Trial
Australia 2014280956 ➤ Try a Free Trial
Canada 2549730 ➤ Try a Free Trial
China 1925875 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Chubb
Cerilliant
Johnson and Johnson
Baxter
McKesson
AstraZeneca
Fish and Richardson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.